enVVeno Medical 将来の成長

Future 基準チェック /26

enVVeno Medicalは、32.9%と96.7%でそれぞれ年率32.9%で利益と収益が成長すると予測される一方、EPSはgrowで41.7%年率。

主要情報

32.9%

収益成長率

41.7%

EPS成長率

Medical Equipment 収益成長	14.2%
収益成長率	96.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	06 Aug 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:5HJ - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	22	-19	N/A	-7	1
12/31/2025	4	-25	N/A	7	1
12/31/2024	N/A	-22	N/A	-24	1
9/30/2024	N/A	-21	-17	-17	N/A
6/30/2024	N/A	-21	-17	-17	N/A
3/31/2024	N/A	-22	-17	-17	N/A
12/31/2023	N/A	-24	-19	-19	N/A
9/30/2023	N/A	-24	-18	-18	N/A
6/30/2023	N/A	-25	-18	-18	N/A
3/31/2023	N/A	-26	-17	-17	N/A
12/31/2022	N/A	-25	-16	-16	N/A
9/30/2022	N/A	-27	-15	-15	N/A
6/30/2022	N/A	-24	-13	-13	N/A
3/31/2022	N/A	-19	-12	-11	N/A
12/31/2021	N/A	-17	-12	-12	N/A
9/30/2021	N/A	-12	-12	-11	N/A
6/30/2021	N/A	-12	-12	-12	N/A
3/31/2021	N/A	-11	-11	-10	N/A
12/31/2020	N/A	-10	-8	-8	N/A
9/30/2020	N/A	-7	-7	-7	N/A
6/30/2020	N/A	-7	-6	-5	N/A
3/31/2020	N/A	-7	-6	-6	N/A
12/31/2019	0	-8	-6	-6	N/A
9/30/2019	0	-7	-6	-6	N/A
6/30/2019	0	-7	-6	-6	N/A
3/31/2019	0	-13	-6	-6	N/A
12/31/2018	0	-16	-6	-6	N/A
9/30/2018	0	-18	-6	-6	N/A
6/30/2018	0	-19	N/A	-6	N/A
3/31/2018	0	-12	N/A	-5	N/A
12/31/2017	0	-8	N/A	-4	N/A
9/30/2017	1	-7	N/A	-4	N/A
6/30/2017	1	-5	N/A	-3	N/A
3/31/2017	1	-6	N/A	-3	N/A
12/31/2016	1	-6	N/A	-3	N/A
9/30/2016	0	-5	N/A	-4	N/A
12/31/2015	N/A	-1	N/A	-2	N/A
12/31/2014	0	-1	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 5HJ今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 5HJ今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 5HJ今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 5HJの収益 ( 96.7% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 5HJの収益 ( 96.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 5HJの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

enVVeno Medical 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast to breakeven in 2026

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

enVVeno Medical Corporation, Annual General Meeting, Dec 18, 2024

Envveno Medical Successfully Initiates 6-Month Pre-Clinical Glp Study Evaluating Envve(R)

New major risk - Shareholder dilution

enVVeno Medical Corporation has filed a Follow-on Equity Offering.

No longer forecast to breakeven

enVeno Medical Corporation Announces Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the VenoValve(R) Pivotal Trial

enVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting

New minor risk - Profitability

enVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

enVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer

Forecast to breakeven in 2026

enVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve

New major risk - Share price stability

Forecast to breakeven in 2026

enVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

enVVeno Medical Corporation, Annual General Meeting, Dec 05, 2023

New minor risk - Shareholder dilution

enVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study

New major risk - Share price stability

Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer

Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria

Insufficient new directors

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

enVVeno Medical Corporation, Annual General Meeting, Nov 30, 2022

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Hancock Jaffe Laboratories, Inc Begins Enrollment for the U.S. Pivotal Trial for the Venovalve, Potential Treatment for Deep Venous Chronic Venous Insufficiency

Forecast to breakeven in 2024

New 90-day low: €5.90

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $35.999992 million.

Hancock Jaffe Laboratories, Inc. Appoints Craig Glynn Chief Financial Officer

Hancock Jaffe Receives Formal Notification from the Nasdaq Hearings Panel

New 90-day low: €5.91

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘